Highest-materiality recent filing
ISCO agrees to sell Lifeline Cell Technology to ATCC for $25M in cash
Purchase price $25M, subject to net working capital, cash, and debt adjustments; closing expected Q3 2026.
International Stem Cell Corp's CFO Sophia Garnette resigns effective April 1, 2022
Sophia Garnette, Principal Financial Officer and VP of Legal Affairs and Operations, submitted resignation.
On April 25, 2022, International Stem Cell Corporation, a Delaware corporation (the “Company”) appointed Dr. Russell Kern as its principal financial officer effective immediately.
On February 1, 2022, Sophia Garnette, Principal Financial Officer and VP of Legal Affairs and Operations of International Stem Cell Corporation (the "Company"), submitted her resignation, to be effective on April 1, 2022.
Max materiality 0.75 · Median 0.45 · Most common event debt